Tristel DUO is effective against:
*VIRUSES (30-Second Contact Time)
- Norovirus
- Herpes simplex virus Type 1
- Poliovirus Type 1
- Adenovirus Type 5
- 2009-H1N1 Influenza A virus
- +Hepatitis B virus (HBV)
- +Human Immunodeficiency virus Type 1 (HIV)
MYCOBACTERIA (1-Minute Contact Time)
- Mycobacterium bovis BCG
(EPA approved surrogate of Mycobacterium tuberculosis)
FUNGI (1-Minute Contact Time)
- Trichophyton interdigitale
- Candida albicans
MULTI-DRUG RESISTANT BACTERIA (2-Minute Contact Time)
- Multi-Drug resistant Streptococcus pneumoniae
- Multi-Drug resistant Acinetobacter baumannii (MDRAB)
DRUG RESISTANT BACTERIA (2 Minute Contact Time)
- Methicillin-Resistant Staphylococcus aureus (MRSA)
- Carbapenem-resistant Klebsiella pneumoniae (CRE)
BACTERIA (2-Minute Contact Time)
- Pseudomonas aeruginosa
- Staphylococcus aureus
- Escherichia coli (E. coli) 0157:H7
- Extended-spectrum beta-lactamase (ESBL) producing Escherichia coli (E.coli)
- Neisseria gonorrhoea
- Streptococcus agalactiae
- Enterobacter cloacae
- Staphylococcus epidermidis
- Salmonella enterica
- Serratia marcescens
- Burkholderia cepacia
Breaks down Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA).
+KILLS HIV-1 AND HBV ON PRE-CLEANED ENVIRONMENTAL SURFACES/OBJECTS PREVIOUSLY SOILED WITH BLOOD/ BODY FLUIDS
in health care settings or other settings in which there is an expected likelihood of soiling of inanimate surfaces/objects with blood/body fluids and in which the surfaces/objects likely to be soiled with blood/body fluids can be associated with the potential for transmission of HIV-1 (associated with AIDS) and HBV.
Antimicrobial Products Registered with EPA for Claims Against Common Pathogens
Tristel Duo is included in the following lists of antimicrobial products registered by EPA and is effective against common pathogens, as indicated in the list titles. EPA-registered antimicrobial products may not make efficacy claims against these pathogens unless the Agency has reviewed data to support the claim and approved the claim on the label.
*When rare or novel viruses cause outbreaks of disease, there may be few if any disinfectants that have been tested and registered for use against that specific pathogen. To prepare for situations like these, EPA created the EVP guidance a voluntary process which allows disinfectant manufacturers to submit data to EPA demonstrating a product’s efficacy against difficult-to-inactivate viruses. In the event of an outbreak that meets certain criteria, EPA triggers the EVP guidance for a specific virus. In doing so, EPA authorizes companies whose products have EVP claims to make statements on their websites, social media, and technical literature about their product’s expected efficacy against the emerging virus.